Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:4/16/2015)... 16, 2015  Amgen (NASDAQ: AMGN ) today ... results on Tuesday, April 21, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
(Date:4/16/2015)... April 16, 2015 Today, Kenneth C. Frazier ... Co., Inc., was elected chairman of the Board of the ... meeting, PhRMA,s president and CEO John J. Castellani ... New Officers Elected to PhRMA Board ... Ian C. Read , chairman and CEO of Pfizer, ...
(Date:4/16/2015)... 2015  Rosewind Corporation (OTCMKTS: RSWN) announced today ... a newly formed specialty healthcare company focused on ... urological disorders. The merged company, which is expected ... operations and incorporates the pipeline assets of both ... is to build a late-stage and commercial pipeline ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... 2015 More than 2000 styles of ... TheCelebrityDresses.com, the #1 online store carrying celebrity inspired special ... have got their perfect dresses for their prom. For ... prom dresses at TheCelebrityDresses.com would be an ideal choice. ... 2000 prom dresses inspired by the most loved styles ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin understood the ... “Tell me what you eat, and I will tell ... stress or sadness has often been attributed to women, ... collected from their Emotional Eating Test reveals ... for different reasons. , Collecting data from 521 emotional ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Riviera ... Dr. Kevin Sadati of the Gallery of Cosmetic ... County’s top beauty experts. The publication focused on ... facial stem cell fat grafting, eyelid surgery, laser resurfacing ... facial plastic surgery has resulted in thousands of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director Kirsten ... 15th, the European Parliament joined its voice with other ... Genocide, “paying tribute, on the eve of the centenary, ... victims who perished in the Ottoman Empire.” In ... timely and needed recognition of a tragic episode in ...
(Date:4/17/2015)... April 17, 2015 At the end ... Lounge and the “Salute to the Oscars” in the ... Hilton Hotel, overlooking the impressive Los Angeles skyline. These ... by Debbie Durkin, LA’s leading producer of sustainable product ... of the world’s premier providers of eco-friendly and socially ...
Breaking Medicine News(10 mins):Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... Ghanshyam Sarda, a prime accused in the expired blood ... senior police official.// ,"We have arrested Ghanshyam ... in court," said Gyanwant Singh, deputy commissioner of police ... was arrested a few days ago. The brothers own ...
... Scientists have identified a naturally occurring enzyme that can ... characteristic of Alzheimer's disease.// The finding may provide researchers ... the brains of Alzheimer's patients and could one day ... University School of Medicine in St. Louis showed earlier ...
... flu vaccine are not as effective as all the hype ... author Dr. Tom Jefferson, coordinator of the Cochrane Vaccines Field ... what vaccines can actually do. I'm hoping American and European ... ,The findings of the study have been published in the ...
... A study assessing a new asthma inhaler revealed that it has ... in 2005 to stop// the funding for Ventolin inhalers in favour ... Salamol inhaler were observed. Only 15 of them were able to ... ineffectiveness of the drug or due to the taste. Asthma stability ...
... for protection against Alzheimer's disease is to be resumed and ... the initial trial. ,The progress of the disease was ... beta amyloid protein causing the disease. But during the second ... of brain inflammation and the study was brought to a ...
... for treatment of obesity, has been found to control blood sugar ... 2. The research was done on 1,047 overweight or obese patients ... ,Some of them were given 5 or 20 mg/day ... a 1 year period. Those on the drug showed a vast ...
Cached Medicine News:Health News:Naturally Occurring Enzyme Can Break Down Key Part of Alzheimer's Plaques 2Health News:Flu Shots-Do we Really Need Them? 2Health News:Alzheimer's Vaccine- A Realistic Prospect 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: